Amplius Wealth Advisors LLC Has $1.18 Million Stake in Eli Lilly and Company (NYSE:LLY)

Amplius Wealth Advisors LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 4.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,526 shares of the company’s stock after acquiring an additional 61 shares during the quarter. Amplius Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $1,178,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Beck Bode LLC bought a new stake in shares of Eli Lilly and Company during the second quarter worth $15,036,000. XTX Topco Ltd acquired a new position in Eli Lilly and Company during the 2nd quarter worth about $546,000. Mill Creek Capital Advisors LLC grew its holdings in Eli Lilly and Company by 8.4% during the 2nd quarter. Mill Creek Capital Advisors LLC now owns 2,498 shares of the company’s stock worth $2,262,000 after acquiring an additional 194 shares during the last quarter. Westwood Wealth Management increased its position in Eli Lilly and Company by 20.1% in the 2nd quarter. Westwood Wealth Management now owns 1,940 shares of the company’s stock valued at $1,756,000 after acquiring an additional 325 shares in the last quarter. Finally, Savoie Capital LLC bought a new position in shares of Eli Lilly and Company in the second quarter worth about $15,315,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Up 2.2 %

NYSE LLY opened at $741.98 on Wednesday. Eli Lilly and Company has a one year low of $614.82 and a one year high of $972.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The firm has a market cap of $704.38 billion, a P/E ratio of 80.21, a P/E/G ratio of 1.52 and a beta of 0.41. The stock’s 50-day moving average is $779.00 and its 200-day moving average is $852.83.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. During the same period in the previous year, the firm posted $0.10 EPS. The business’s quarterly revenue was up 20.4% compared to the same quarter last year. Sell-side analysts anticipate that Eli Lilly and Company will post 12.98 earnings per share for the current fiscal year.

Eli Lilly and Company declared that its Board of Directors has authorized a stock repurchase program on Monday, December 9th that allows the company to buyback $15.00 billion in shares. This buyback authorization allows the company to purchase up to 2% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s leadership believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.81%. The ex-dividend date is Friday, February 14th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s dividend payout ratio is 56.22%.

Insider Buying and Selling at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Barclays decreased their price target on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st. Wolfe Research assumed coverage on Eli Lilly and Company in a research report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price objective on the stock. Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Truist Financial raised their price target on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a report on Thursday, October 10th. Finally, Sanford C. Bernstein initiated coverage on Eli Lilly and Company in a report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price objective for the company. Four investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,002.22.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.